187 related articles for article (PubMed ID: 19229977)
41. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
[TBL] [Abstract][Full Text] [Related]
42. Baseline fractional flow reserve and stent diameter predict optimal post-stent fractional flow reserve and major adverse cardiac events after bare-metal stent deployment.
Samady H; McDaniel M; Veledar E; De Bruyne B; Pijls NH; Fearon WF; Vaccarino V
JACC Cardiovasc Interv; 2009 Apr; 2(4):357-63. PubMed ID: 19463450
[TBL] [Abstract][Full Text] [Related]
43. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
Costa JR; Sousa A; Moreira AC; Costa RA; Cano M; Maldonado G; Campos C; Carballo M; Pavanello R; Sousa JE
JACC Cardiovasc Interv; 2010 Jan; 3(1):12-8. PubMed ID: 20129562
[TBL] [Abstract][Full Text] [Related]
44. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
Hannan EL; Racz M; Walford G; Holmes DR; Jones RH; Sharma S; Katz S; King SB
JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of 2.5-mm sirolimus-eluting stent implantation at lower deployment pressures in very small vessels (<2.5 mm).
Umeda H; Iwase M; Gochi T; Izawa H; Ishiki R; Inagaki H; Shimizu T; Yokota M; Murohara T
Coron Artery Dis; 2009 Mar; 20(2):163-8. PubMed ID: 19293669
[TBL] [Abstract][Full Text] [Related]
46. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
[TBL] [Abstract][Full Text] [Related]
47. The efficacy and safety of PRO-kinetic metal alloy stent in hospitalized patients with acute ST-elevation myocardial infarction (The PROMETHEUS Study).
Lim SY; Park HW; Chung WY; Kim SY; Kim KS; Bae JW; Youn TJ;
J Invasive Cardiol; 2012 Jun; 24(6):270-3. PubMed ID: 22684380
[TBL] [Abstract][Full Text] [Related]
48. Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
Mirabella F; Francaviglia B; Capodanno D; Di Salvo ME; Galassi AR; Ussia GP; Capranzano P; Tamburino C
J Invasive Cardiol; 2009 Apr; 21(4):145-50. PubMed ID: 19342750
[TBL] [Abstract][Full Text] [Related]
49. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
Wöhrle J; Werner GS
Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
[TBL] [Abstract][Full Text] [Related]
50. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
51. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
[TBL] [Abstract][Full Text] [Related]
52. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
53. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry.
Brilakis ES; Wang TY; Rao SV; Banerjee S; Goldman S; Shunk K; Kar B; Holmes DR; Dai D; Chin CT; Harding TM; Roe MT
JACC Cardiovasc Interv; 2010 Oct; 3(10):1068-73. PubMed ID: 20965466
[TBL] [Abstract][Full Text] [Related]
54. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
[TBL] [Abstract][Full Text] [Related]
55. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
Yan BP; Ajani AE; New G; Duffy SJ; Farouque O; Shaw J; Sebastian M; Lew R; Brennan A; Andrianopoulos N; Reid C; Clark DJ;
Int J Cardiol; 2008 Nov; 130(3):374-9. PubMed ID: 18706719
[TBL] [Abstract][Full Text] [Related]
56. Comparison between balloon angioplasty and additional coronary stent implantation for the treatment of drug-eluting stent restenosis: 18-month clinical outcomes.
Sardella G; Colantonio R; De Luca L; Conti G; Di Roma A; Mancone M; Canali E; Benedetti G; Fedele F
J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):469-73. PubMed ID: 19318976
[TBL] [Abstract][Full Text] [Related]
57. A prospective multicentre registry, evaluating real-world usage of the Tryton side branch stent: results of the E-Tryton 150/Benelux registry.
Agostoni P; Foley D; Lesiak M; Belkacemi A; Dens J; Kumsars I; Scott B; Oemrawsingh P; Dubois C; Garcia E; Lefèvre T; Stella PR
EuroIntervention; 2012 Mar; 7(11):1293-300. PubMed ID: 22433192
[TBL] [Abstract][Full Text] [Related]
58. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
59. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization.
Ortolani P; Marzocchi A; Marrozzini C; Palmerini T; Saia F; Taglieri N; Aquilina M; Baldazzi F; Silenzi S; Cooke RM; Reggiani ML; Branzi A
Catheter Cardiovasc Interv; 2007 May; 69(6):790-8. PubMed ID: 17290437
[TBL] [Abstract][Full Text] [Related]
60. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B
EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
